- Home
- CAG vs CNTA Comparison
CAG vs CNTA Comparison
Compare CAG & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAG | CNTA |
|---|---|---|
| Founded | 1919 | 2020 |
| Country | United States | United Kingdom |
| Employees | 26100 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.1B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CAG | CNTA |
|---|---|---|
| Price | $13.48 | $39.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 9 |
| Target Price | $16.88 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 12.4M | 1.6M |
| Earning Date | 04-01-2026 | 05-13-2026 |
| Dividend Yield | ★ 9.84% | N/A |
| EPS Growth | ★ 233.33 | 29.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,500,000,000.00 | $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.61 | $10.95 |
| 52 Week High | $23.37 | $40.26 |
Technical Indicators
Market Signals| Indicator | CAG | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 32.01 | 71.70 |
| Support Level | N/A | $39.36 |
| Resistance Level | $19.48 | $39.86 |
| Average True Range (ATR) | 0.43 | 0.14 |
| MACD | 0.02 | -0.34 |
| Stochastic Oscillator | 5.73 | 47.52 |
Price Performance
Historical ComparisonAbout CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.